Enveric Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Enveric Biosciences, Inc. carries a market capitalization of 6.22M, placing it among publicly traded companies globally. Its enterprise value stands at -2.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.22M |
| Enterprise Value | -2.86M |
Share Statistics
Enveric Biosciences, Inc. currently has 3.94M shares outstanding.
| Shares Outstanding | 3.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | -0.31 |
| P/OCF Ratio | -0.31 |
Financial Position
Enveric Biosciences, Inc. maintains a current ratio of 10.21, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.21 |
| Quick Ratio | 9.63 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -199.52 |
| Return on Assets (ROA) | -139.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Enveric Biosciences, Inc.'s stock has declined approximately -83.76168% over the past 52 weeks. The 50-day moving average sits at 1.46, while the 200-day moving average is 2.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | -83.76168% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 2.13 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.57M, while operating income came in at -8.73M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.73M |
| Pretax Income | -8.73M |
| Net Income | -8.73M |
| EBITDA | -8.57M |
| EBIT | -8.73M |
| Earnings Per Share (EPS) | -4.51 |
Balance Sheet
Total book value stands at 8.08M, with working capital of 7.93M providing operational flexibility.
| Cash & Cash Equivalents | 8.30M |
| Total Debt | N/A |
| Net Debt | -8.30M |
| Equity (Book Value) | 8.08M |
| Book Value Per Share | 2.05 |
| Working Capital | 7.93M |
Cash Flow
Enveric Biosciences, Inc. produced -8.56M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.56M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.56M |
| FCF Per Share | -4.42 |
Dividends & Yields
The company's payout ratio of 14.78 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 14.78 |
| Shareholder Yield | -258.30 |
| FCF Yield | -320.29 |
Stock Splits
Enveric Biosciences, Inc.'s most recent stock split took place on October 28, 2025 with a 12:1 split ratio.
| Last Split Date | 10/28/2025 |
| Split Ratio | 12:1 |
Scores
Enveric Biosciences, Inc. posts an Altman Z-Score of -17.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.08 |